Daniel Speidel

Daniel Speidel

Company: Breakpoint Therapeutics

Job title: Co-Managing Director

Bio:

Dr. Daniel Speidel is Managing Director and co-founder of Breakpoint Therapeutics GmbH, a Hamburg-based company dedicated to the discovery of anti-cancer drugs that target the DNA Damage Response (DDR) in cancer cells. Prior to commencing his role at Breakpoint he was the Vice President Initiative Leader Oncology at Evotec where his main task was to facilitate formation of a spin-off company that became Breakpoint. Dr. Speidel is a biochemist by training and has more than 20 years’ experience in cancer research focusing on cellular DNA damage responses and p53 in particular. Before joining Evotec he led an academic group at Children’s Medical Research Institute/University of Sydney. A former management consultant with McKinsey & Company, he has also advised several research-related organizations and other institutions on matters of strategic importance.

Seminars:

Panel Discussion: What is the Role of DDR-targeted Therapies in the Wider Oncology Portfolio? 3:45 pm

Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.